These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
147 related articles for article (PubMed ID: 3897455)
21. Is stimulation of both D1 and D2 receptors necessary for the expression of dopamine-mediated behaviors? White FJ; Bednarz LM; Wachtel SR; Hjorth S; Brooderson RJ Pharmacol Biochem Behav; 1988 May; 30(1):189-93. PubMed ID: 2902644 [TBL] [Abstract][Full Text] [Related]
22. Comparison of the dopaminergic effects of apomorphine and (-)-N-n-propylnorapomorphine. Menon MK; Clark WG; Neumeyer JL Eur J Pharmacol; 1978 Nov; 52(1):1-9. PubMed ID: 569056 [TBL] [Abstract][Full Text] [Related]
23. Potentiation of apomorphine-induced stereotyped behaviour by acute treatment with dopamine depleting agents: a potential role for an increased stimulation of D1 dopamine receptors. Vasse M; Protais P Neuropharmacology; 1989 Sep; 28(9):931-9. PubMed ID: 2554186 [TBL] [Abstract][Full Text] [Related]
24. Chronic L-dopa treatment of rats and mice does not change the sensitivity of post-synaptic dopamine receptors. Jackson DM; Jenkins OF; Malor R; Christie MJ; Gregory P Naunyn Schmiedebergs Arch Pharmacol; 1983 Dec; 324(4):271-4. PubMed ID: 6686648 [TBL] [Abstract][Full Text] [Related]
25. Behavioural evidence for supersensitivity of postsynaptic dopamine receptors in the mesolimbic system after chronic administration of desipramine. Spyraki C; Fibiger HC Eur J Pharmacol; 1981 Sep; 74(2-3):195-206. PubMed ID: 7198991 [TBL] [Abstract][Full Text] [Related]
26. alpha-methyl-p-tyrosine inhibition of a conditioned avoidance response: reversal by dopamine applied to the nucleus accumbens. Bracs PU; Jackson DM; Gregory P Psychopharmacology (Berl); 1982; 77(2):159-63. PubMed ID: 6812133 [TBL] [Abstract][Full Text] [Related]
27. Postsynaptic dopamine/adenosine interaction: I. Adenosine analogues inhibit dopamine D2-mediated behaviour in short-term reserpinized mice. Ferré S; Herrera-Marschitz M; Grabowska-Andén M; Ungerstedt U; Casas M; Andén NE Eur J Pharmacol; 1991 Jan; 192(1):25-30. PubMed ID: 1828236 [TBL] [Abstract][Full Text] [Related]
28. The relative importance of dopamine and noradrenaline receptor stimulation for the restoration of motor activity in reserpine or alpha-methyl-p-tyrosine pre-treated mice. Dolphin AC; Jenner P; Marsden CD Pharmacol Biochem Behav; 1976 Jun; 4(6):661-70. PubMed ID: 981283 [TBL] [Abstract][Full Text] [Related]
29. Enhancement by a single dose of reserpine (plus alpha methyl-p-tyrosine) of the central stimulatory effects evoked by dopamine D-1 and D-2 agonists in the mouse. Ross SB; Jackson DM; Wallis EM; Edwards SR Naunyn Schmiedebergs Arch Pharmacol; 1988 May; 337(5):512-8. PubMed ID: 3261844 [TBL] [Abstract][Full Text] [Related]
30. Behavioral effects of a dimethylsulfonium analog of dopamine after injection into the nucleus accumbens and the striatum. Boldry R; Chang Y; Miller DD; Uretsky NJ Pharmacol Biochem Behav; 1986 Feb; 24(2):223-8. PubMed ID: 3081914 [TBL] [Abstract][Full Text] [Related]
31. The effects on central dopamine function of chronic L-dopa (methyl ester hydrochloride) treatment of mice. Tabar J; Hashizume M; Cook CJ; Beart PM; Jackson DM Pharmacol Biochem Behav; 1989 May; 33(1):139-46. PubMed ID: 2789405 [TBL] [Abstract][Full Text] [Related]
32. Behavioural, biochemical and electrophysiological studies on the motor depressant and stimulant effects of bromocriptine. Jackson DM; Martin LP; Larsson LG; Cox RF; Waszczak BL; Ross SB Naunyn Schmiedebergs Arch Pharmacol; 1990 Sep; 342(3):290-9. PubMed ID: 2126347 [TBL] [Abstract][Full Text] [Related]
33. Multifocal sites of action involved in dopaminergic-cholinergic neuronal interactions in yawning. Ushijima I; Mizuki Y; Yamada M Psychopharmacology (Berl); 1988; 95(1):34-7. PubMed ID: 3133698 [TBL] [Abstract][Full Text] [Related]
34. Time course of bromocriptine induced excitation in the rat: behavioural and biochemical studies. Jackson DM; Mohell N; Georgiev J; Bengtsson A; Larsson LG; Magnusson O; Ross SB Naunyn Schmiedebergs Arch Pharmacol; 1995 Feb; 351(2):146-55. PubMed ID: 7539523 [TBL] [Abstract][Full Text] [Related]
35. Locomotor hypokinesia in the reserpine-treated rat: drug effects from the corpus striatum and nucleus accumbens. Johnels B Pharmacol Biochem Behav; 1982 Aug; 17(2):283-9. PubMed ID: 7134238 [TBL] [Abstract][Full Text] [Related]
36. Different roles of D-1 and D-2 dopamine receptors involved in locomotor activity of supersensitive mice. Rubinstein M; Gershanik O; Stefano FJ Eur J Pharmacol; 1988 Apr; 148(3):419-26. PubMed ID: 2968273 [TBL] [Abstract][Full Text] [Related]
37. Effects of acute dopamine depletion on responsiveness to D1 and D2 receptor agonists in infant and weanling rat pups. Moody CA; Spear LP Psychopharmacology (Berl); 1992; 107(1):39-49. PubMed ID: 1350350 [TBL] [Abstract][Full Text] [Related]
38. Relative dopamine D1 and D2 receptor affinity and efficacy determine whether dopamine agonists induce hyperactivity or oral stereotypy in rats. Arnt J; Bøgesø KP; Hyttel J; Meier E Pharmacol Toxicol; 1988 Mar; 62(3):121-30. PubMed ID: 3259694 [TBL] [Abstract][Full Text] [Related]
39. A behavioural study of the changes in the central nervous system of mice after subchronic treatment with the selective dopamine autoreceptor agonist 3-PPP (dl-3-[3-hydroxyphenyl]-N-n-propylpiperidine). Jackson D; Carlsson A; Hjorth S; Lindberg P J Neural Transm; 1982; 53(4):233-45. PubMed ID: 6286867 [TBL] [Abstract][Full Text] [Related]
40. Involvement of dopaminergic receptor subtypes in straub tail behaviour in mice. Zarrindast MR; Bayat A; Shafaghi B Gen Pharmacol; 1993 Jan; 24(1):127-30. PubMed ID: 8097737 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]